Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Execs On The Move: C-Suite Changes at Nuvectra, Biogennix, Microbot

Executive Summary

An experienced board member steps up to fill the CEO slot at neurostim firm Nuvectra; a new CFO is taken on board at osteobiological products company Biogennix; and Microbot Medical's chief operating officer resigns.

You may also be interested in...



CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients

After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.

Novartis Looks To Take Its Diversity Show On The Road

Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.

New Material Safety Reports Highlight Lack Of Data To Fully Evaluate Adverse Reactions

The US FDA and ECRI released four reports about the safety of certain materials used in medical devices. While the risks seem to be comparatively low, they note the quality of literature is lacking to make broad evaluations.

Topics

UsernamePublicRestriction

Register

MT124636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel